CD8A and Miyoshi myopathy: The clinical finding of an association between improved clinical outcome and reduced Treg/Th17 ratios (8) or Treg frequency (9, 10) and oligoclonal expansion of terminal effector CD8+ T cells (TTE) (11) suggests Treg and oligoclonal expansion of TTE as key players of immune surveillance in MM.